These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11911803)

  • 21. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ
    J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS; Koch-Henriksen N; Bendtzen K
    Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epitope specificity of neutralizing antibodies against IFN-beta.
    Gneiss C; Reindl M; Berger T; Lutterotti A; Ehling R; Egg R; Deisenhammer F
    J Interferon Cytokine Res; 2004 May; 24(5):283-90. PubMed ID: 15153311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
    Garg N; Weinstock-Guttman B; Bhasi K; Locke J; Ramanathan M
    Mult Scler; 2007 Aug; 13(7):895-9. PubMed ID: 17468449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.
    Malucchi S; Sala A; Gilli F; Bottero R; Di Sapio A; Capobianco M; Bertolotto A
    Neurology; 2004 Jun; 62(11):2031-7. PubMed ID: 15184610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis.
    Namaka M; Pollitt-Smith M; Gupta A; Klowak M; Vasconcelos M; Turcotte D; Gong Y; Melanson M
    Curr Med Res Opin; 2006 Feb; 22(2):223-39. PubMed ID: 16466595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
    Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of four different assays for the detection of binding antibodies against interferon-beta.
    Gneiss C; Brugger M; Millonig A; Fogdell-Hahn A; Rudzki D; Hillert J; Berger T; Reindl M; Deisenhammer F
    Mult Scler; 2008 Jul; 14(6):830-6. PubMed ID: 18535018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis.
    Ross C; Clemmesen KM; Sørensen PS; Koch-Henriksen N; Bendtzen K
    Mult Scler; 2006 Feb; 12(1):39-46. PubMed ID: 16459718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.
    Sørensen PS; Deisenhammer F; Duda P; Hohlfeld R; Myhr KM; Palace J; Polman C; Pozzilli C; Ross C;
    Eur J Neurol; 2005 Nov; 12(11):817-27. PubMed ID: 16241970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
    Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
    J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
    Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M; Janghorbani M; Shaygannejad V
    Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
    Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
    Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Flow cytometry model for the detection of neutralizing antibodies against of IFN-β].
    Villa-Camacho JC; Vargas-Zambrano JC; González JM
    Biomedica; 2012; 32(4):617-22. PubMed ID: 23715237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS.
    Zang YC; Yang D; Hong J; Tejada-Simon MV; Rivera VM; Zhang JZ
    Neurology; 2000 Aug; 55(3):397-404. PubMed ID: 10932275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
    Paolicelli D; Iannazzo S; Santoni L; Iaffaldano A; Di Lecce V; Manni A; Lavolpe V; Tortorella C; D'Onghia M; Direnzo V; Puma E; Trojano M
    PLoS One; 2016; 11(7):e0159214. PubMed ID: 27390865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.